Viaskin Peanut patch, developed to fight peanut allergies, has furnished promising results in the early stage clinical tests. About 3 million Americans are allergic to nuts and most of them are allergic especially to peanuts. However, the newly developed allergy patch might prove to be a potential solution for those suffering from peanut allergy. The result of the clinical trial was presented in the Sunday’s annual meeting of the American Academy of Allergy, Asthma and Immunology, Houston, Texas. According to the researchers the Viaskin Peanut treatment gradually familiarizes the skin cells to peanuts and thus reduces the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen.
The skin patch has been tested across multiple countries on a number of individuals to check its safety and efficacy. The results showed that the patch is efficient in preventing life threatening reactions to peanuts. The skin patch has been developed by a France-based biotech firm, DBV. Viaskin Peanut patch can be worn as a simple skin patch. The clinical trial was conducted on 221 subjects between the ages of 6 and 55 years. The participants belonged to the U.S., Poland, the Netherlands, Canada and France.
The treatment includes infusing a small amount of peanut protein in the outer layer of the skin which leads to an immune response. However, the response is not enough to release antigens into the blood and thus it helps in preventing allergic shocks. The participants were examined to determine the amount of peanut protein required to elicit a reaction, following which they were given the patches of 50,100 or 250 micrograms of peanut protein as per their need. Researchers tested the participants after one year to see if their threshold against the protein increased. For most of them, the treatment was found to be significantly effective.